CMPS (Compass Pathways) YoY EBITDA Growth: -371.21% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CMPS Compass Pathways PLC CMPS
33 GF Score
Price $13.29
! 1 Warning Sign
View Full Analysis

What is Compass Pathways YoY EBITDA Growth?

Compass Pathways CMPS +0.45% 33 YoY EBITDA Growth is -371.21% as of Jun. 2026. GuruFocus rates CMPS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Compass Pathways's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -371.21%.

Compass Pathways's EBITDA per Share for the three months ended in Jun. 2026 was $-1.87.

Compass Pathways YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Compass Pathways's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Pathways YoY EBITDA Growth Chart

Compass Pathways Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial 35.55 -19.90 20.15 -29.10 -38.50

Compass Pathways Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.39 -164.27 -66.50 528.31 -371.21
CMPS
33GF Score
Compass Pathways PLC CMPS
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Pathways YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Compass Pathways's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-3.054--2.205)/ | -2.205 |
=-38.50 %

Compass Pathways's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-1.866--0.396)/ | -0.396 |
=-371.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -371.21% mean?
Compass Pathways (CMPS) has a YoY EBITDA Growth of -371.21% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Compass Pathways and its competitors.
Is Compass Pathways' YoY EBITDA Growth too high?
Compass Pathways' current YoY EBITDA Growth is -371.21%. Overall, Compass Pathways has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Compass Pathways' YoY EBITDA Growth compare to ASTH and SNDA?
Compass Pathways' YoY EBITDA Growth of -371.21% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Compass Pathways and its competitors. Compass Pathways's current YoY EBITDA Growth is -371.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Pathways stock overvalued right now?
Compass Pathways (CMPS) has a current YoY EBITDA Growth of -371.21%. The current YoY EBITDA Growth is -371.21%. Compass Pathways' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Compass Pathways (CMPS), the current YoY EBITDA Growth is -371.21% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compass Pathways Business Description

Other Exchanges CMPSN:Mexico5Y6:Germany
Address 33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
33GF Score

Get the complete analysis for CMPS

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.29
Price